Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Pro-Endocrine Pancreatic Islet Transcriptional Program Established During Development Is Retained in Human Gallbladder Epithelial Cells.
Joglekar MV, Sahu S, Wong WKM, Satoor SN, Dong CX, Farr RJ, Williams MD, Pandya P, Jhala G, Yang SNY, Chew YV, Hetherington N, Thiruchevlam D, Mitnala S, Rao GV, Reddy DN, Loudovaris T, Hawthorne WJ, Elefanty AG, Joglekar VM, Stanley EG, Martin D, Thomas HE, Tosh D, Dalgaard LT, Hardikar AA. Joglekar MV, et al. Among authors: yang sny. Cell Mol Gastroenterol Hepatol. 2022;13(5):1530-1553.e4. doi: 10.1016/j.jcmgh.2022.01.008. Epub 2022 Jan 12. Cell Mol Gastroenterol Hepatol. 2022. PMID: 35032693 Free PMC article.
Structural mechanisms of inactivation in scabies mite serine protease paralogues.
Fischer K, Langendorf CG, Irving JA, Reynolds S, Willis C, Beckham S, Law RH, Yang S, Bashtannyk-Puhalovich TA, McGowan S, Whisstock JC, Pike RN, Kemp DJ, Buckle AM. Fischer K, et al. J Mol Biol. 2009 Jul 24;390(4):635-45. doi: 10.1016/j.jmb.2009.04.082. Epub 2009 May 7. J Mol Biol. 2009. PMID: 19427318
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. Cerchietti LC, et al. Among authors: yang sn. Nat Med. 2024 May;30(5):1503. doi: 10.1038/s41591-024-02957-0. Nat Med. 2024. PMID: 38570701 No abstract available.
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, Weng DS, Xu X, Li YZ, Tang Y, Zhang WH, Li JY, Zheng X, Wang QJ, Li YQ, Xiang T, Zhou L, Yang SN, Wu C, Huang RX, He J, Du WJ, Chen LJ, Wu YN, Xu B, Shen Q, Zhang Y, Jiang JT, Ren XB, Xia JC. Pan QZ, et al. Among authors: yang sn. Signal Transduct Target Ther. 2024 Apr 3;9(1):79. doi: 10.1038/s41392-024-01788-2. Signal Transduct Target Ther. 2024. PMID: 38565886 Free PMC article. Clinical Trial.
446 results